Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Pitolisant · Wakix, HBS-201

Small molecule · Antagonist of histamine H3 receptor (HRH3) · developed by Harmony

Approved FDA, Aug 2019
HRMY Developer
7 Registered trials

What is Pitolisant?

Pitolisant is an orally given histamine-3 (H3) receptor antagonist/inverse agonist. It acts on H3 receptors, which regulate histamine release in the brain, and it is studied in sleep disorders and other neurological conditions including Prader-Willi syndrome, myotonic dystrophy 1, idiopathic hypersomnia and restless legs syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Wakix, HBS-201, BF-2649
Drug type
Small molecule
Targets
histamine H3 receptor (HRH3)
Mechanism
Antagonist of histamine H3 receptor (HRH3)
Pathways
histaminergic neurotransmission
Therapy area
Neurology
Developer
Harmony (HRMY)
FDA status
Approved as Wakix (August 14, 2019), NDA211150 · FDA label
UNII
4BC83L4PIY

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 13, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05581576 Phase 4 Restless Legs Syndrome Unknown HRMY
NCT06366464 Phase 3 Prader-Willi Syndrome Recruiting HRMY
NCT05156047 Phase 3 Idiopathic Hypersomnia Completed HRMY
NCT04886518 Phase 2 Myotonic Dystrophy 1 Completed HRMY
NCT04257929 Phase 2 Prader-Willi Syndrome Completed HRMY
NCT07860736 Phase 1 Healthy Participants Completed HRMY
NCT07051252 Phase 1 Narcolepsy Completed HRMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Excessive Daytime SleepinessHealthy ParticipantsIdiopathic HypersomniaMyotonic Dystrophy 1NarcolepsyPrader-Willi SyndromeRestless Legs Syndrome

More from Harmony

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the HRMY page.

Follow HRMY, the company behind Pitolisant

See HRMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

HRMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.